{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T15:57:58Z","timestamp":1785859078172,"version":"3.56.0"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:p>\n                    A 60-year-old woman with synchronous papillary and medullary thyroid carcinomas (MTC) underwent total thyroidectomy and adjuvant therapy. In later course of her MTC disease, an elevation of serum calcitonin prompted\n                    <jats:sup>68<\/jats:sup>\n                    Ga-DOTATATE imaging, revealing mildly avid loco-regional and osseous metastases as well as non-avid nodal and hepatic metastases.\n                    <jats:sup>68<\/jats:sup>\n                    Ga-FAPI PET\/CT demonstrated superior detection compared with\n                    <jats:sup>68<\/jats:sup>\n                    Ga-DOTATATE PET\/CT, particularly in hepatic lesions.\n                    <jats:sup>177<\/jats:sup>\n                    Lu-FAPI-2286 radioligand therapy (RLT) was administered but failed to achieve biochemical response, though it was well tolerated. This case highlights the diagnostic advantage of FAP-targeted imaging in advanced MTC and underscores the need for standardized RLT protocols and exploration of combination therapeutic strategies.\n                  <\/jats:p>","DOI":"10.1097\/rlu.0000000000006455","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T18:00:31Z","timestamp":1776276031000},"page":"e802-e804","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Superior Diagnostic Performance of \u2076\u2078Ga-FAPI PET\/CT Compared With \u2076\u2078Ga-DOTATATE PET\/CT in Medullary Thyroid Carcinoma"],"prefix":"10.1097","volume":"51","author":[{"given":"Amin","family":"Saber Tanha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haniye","family":"Elahifard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohsen","family":"Saberifar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasrin","family":"Raeisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2973-2251","authenticated-orcid":false,"given":"Emran","family":"Askari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,4,10]]},"reference":[{"key":"R1-20260803","doi-asserted-by":"crossref","first-page":"e24007","DOI":"10.1530\/EO-24-0077","article-title":"Overview of management and therapeutic advances in medullary thyroid cancer","volume":"5","author":"Jara","year":"2025","journal-title":"Endocrine Oncology"},{"key":"R2-20260803","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-031-80396-3_1","article-title":"What is new in diagnostics and management of medullary thyroid carcinoma","volume":"223","author":"Raue","year":"2025","journal-title":"Recent Results Cancer Res"},{"key":"R3-20260803","doi-asserted-by":"crossref","first-page":"3250","DOI":"10.1210\/jc.2018-00193","article-title":"Comparison of 68Ga PET\/CT to other imaging studies in medullary thyroid cancer: superiority in detecting bone metastases","volume":"103","author":"Castroneves","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"R4-20260803","first-page":"19","article-title":"Gallium-68 Dotatate PET\/CT is superior to other imaging modalities in the detection of medullary carcinoma of the thyroid in the presence of high serum calcitonin","volume":"18","author":"Tran","year":"2015","journal-title":"Hell J Nucl Med"},{"key":"R5-20260803","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s00259-009-1204-z","article-title":"Comparison of 68Ga-DOTATATE and 18F-fluorodeoxyglucose PET\/CT in the detection of recurrent medullary thyroid carcinoma","volume":"37","author":"Conry","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R6-20260803","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s13044-025-00250-x","article-title":"The utility of 68Ga-DOTATATE and 18F-FDG PET\/CT in predicting the response to tyrosine kinase inhibitors in patients with advanced medullary thyroid cancer","volume":"18","author":"Jager","year":"2025","journal-title":"Thyroid Res"},{"key":"R7-20260803","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s12149-020-01494-3","article-title":"Clinical impact of 68Ga-DOTATATE PET-CT imaging in patients with medullary thyroid cancer","volume":"34","author":"Tuncel","year":"2020","journal-title":"Ann Nucl Med"},{"key":"R8-20260803","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.amjsurg.2022.03.046","article-title":"68Ga-DOTATATE-PET shows promise for diagnosis of recurrent or persistent medullary thyroid cancer: a systematic review","volume":"224","author":"Pajak","year":"2022","journal-title":"The American Journal of Surgery"},{"key":"R9-20260803","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1158\/2159-8290.CD-24-0897","article-title":"CTR-FAPI PET enables precision management of medullary thyroid carcinoma","volume":"15","author":"Kong","year":"2025","journal-title":"Cancer Discov"},{"key":"R10-20260803","doi-asserted-by":"crossref","first-page":"e615","DOI":"10.1097\/RLU.0000000000005469","article-title":"Variable tracer avidity and interlesional heterogeneity on 18F-FDG, 68Ga-DOTATATE, and 68Ga-DOTA-FAPi-04 PET\/CT imaging in a single individual patient with progressive metastatic medullary thyroid carcinoma","volume":"49","author":"Edamadaka","year":"2024","journal-title":"Clin Nucl Med"},{"key":"R11-20260803","doi-asserted-by":"crossref","first-page":"e547","DOI":"10.1097\/RLU.0000000000005723","article-title":"Combination therapy with 177Lu-FAPI-2286 and tyrosine kinase inhibitor: a novel approach for treating metastatic medullary thyroid carcinoma","volume":"50","author":"Raeisi","year":"2025","journal-title":"Clin Nucl Med"},{"key":"R12-20260803","doi-asserted-by":"crossref","first-page":"e209","DOI":"10.1097\/RLU.0000000000005605","article-title":"Application of 99mTc-FAPI-46 imaging in a patient with medullary thyroid carcinoma","volume":"50","author":"Raeisi","year":"2025","journal-title":"Clin Nucl Med"},{"key":"R13-20260803","article-title":"FAPI-based theranostics in medullary thyroid cancer: a viable alternative when somatostatin receptor-based theranostics show limited efficacy\u2014a clinical experience","author":"Saber Tanha","year":"2025","journal-title":"Clin Nucl Med"},{"key":"R14-20260803","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1186\/s12885-025-15101-z","article-title":"Anatomical\u2013biochemical discordance and prognostic role of bone metastases in advanced MTC treated with [177Lu]Lu-DOTA-TATE","volume":"25","author":"Bilgic","year":"2025","journal-title":"BMC Cancer"},{"key":"R15-20260803","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1097\/RLU.0000000000000706","article-title":"Medullary thyroid carcinoma (MTC) treated with 177Lu-DOTATATE PRRT","volume":"40","author":"Makis","year":"2015","journal-title":"Clin Nucl Med"},{"key":"R16-20260803","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/hed.26024","article-title":"Clinical utility of 177 Lu-DOTATATE PRRT in somatostatin receptor-positive metastatic medullary carcinoma of thyroid patients with assessment of efficacy, survival analysis, prognostic variables, and toxicity","volume":"42","author":"Parghane","year":"2020","journal-title":"Head Neck"},{"key":"R17-20260803","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1097\/MNM.0000000000001205","article-title":"Efficacy and safety of concomitant 177Lu-DOTATATE and low-dose capecitabine in advanced medullary thyroid carcinoma: a single-centre experience","volume":"41","author":"Satapathy","year":"2020","journal-title":"Nucl Med Commun"},{"key":"R18-20260803","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ando.2022.08.001","article-title":"Feasibility and therapeutic potential of the 68Ga\/177Lu-DOTATATE theranostic pair in patients with metastatic medullary thyroid carcinoma","volume":"84","author":"Dadgar","year":"2023","journal-title":"Ann Endocrinol (Paris)"},{"key":"R19-20260803","doi-asserted-by":"crossref","first-page":"e444","DOI":"10.1097\/RLU.0000000000004164","article-title":"First-in-human experience with 177Lu-DOTAGA.(SA.FAPi)2 Therapy in an uncommon case of aggressive medullary thyroid carcinoma clinically mimicking as anaplastic thyroid cancer","volume":"47","author":"Ballal","year":"2022","journal-title":"Clin Nucl Med"},{"key":"R20-20260803","doi-asserted-by":"crossref","first-page":"4112","DOI":"10.1007\/s00259-023-06348-4","article-title":"[68Ga]Ga-DOTA-FAPI-04 PET\/CT depicts metastases from medullary thyroid cancer that [68Ga]Ga-DOTATOC PET\/CT missed","volume":"50","author":"Al-Ibraheem","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/RLU.0000000000006455","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T15:03:56Z","timestamp":1785855836000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/RLU.0000000000006455"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,10]]},"references-count":20,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000006455","relation":{},"ISSN":["0363-9762","1536-0229"],"issn-type":[{"value":"0363-9762","type":"print"},{"value":"1536-0229","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,10]]},"assertion":[{"value":"2025-12-19","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-06","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}